Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII

Thrombosis and Haemostasis

Volumn 98, Issue 6, 2007, Pages 1188-1192

  Singleton, Evelyn ^a   Smith, Jude ^a   Kavanagh, Mary ^a   Nolan, Beatrice ^a   White, Barry ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

FVIII inhibitor; FVIII BHK; FVIII CHO; Recombinant factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; DESMOPRESSIN; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CELL STRAIN BHK; CHILD; CHO CELL; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; IRELAND; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANIMALS; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHO CELLS; COAGULANTS; CRICETINAE; CRICETULUS; FACTOR VIII; HEALTH CARE SURVEYS; HEMOPHILIA A; HUMANS; IRELAND; KIDNEY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37049032877     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-06-0408     Document Type: Article

References (23)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-435.
2. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85: 7-13.
3. Rosendaal FR, Nieuwenhuis HK, Van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-2186.
4. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-3745.
5. Astermark J, Oldenburg J, pavlova A, et al. Polymorphisms in the IL10 but not in the IL1 beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-3172.
6. Astermark J. Over-view of inhibitors. Semin Hematol 2006; 43: S3-S7.
7. White GC, DiMichele D, Mertens K, et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
8. Peerlinck K, Arnout J, Gilles JG, et al. A higher than expected incidence of factor VIII inhibitors in multi-transfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-118.
9. Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-86.
10. Sawamoto Y, Prescott R, Zhong D, et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 1998; 79: 62-68.
11. Keeling D. Switching between full-length and B-domain-deleted factor VIII and the risk of inhibitors. Haemophilia 2006; 12: 690-691.
12. Roussel-Robert V, Torchet MF, Legrand F, et al. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. J Thromb Haemost 2003; 1: 2450-2451.
13. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 346-348.
14. Bayer PLC. Kogenate Bayer 250IU, 5001U, & I000IU (Bio-Set). Specific product characteristics. Available at: http://emc.medicines.org.uk. Accessed January 26, 2007.
15. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
16. Aventis. DDAVP Injection [prescribing information]. Bridgewater, NJ: Aventis; 2006.
17. Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-816.
18. Giles AR, Rivard GE, Teitel J, et al. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-148.
19. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12 (Suppl 3): 52-60.
20. Santagostino E, Mancuso M, Van der Bom J, et al. Intensity of treatment/ prophylaxis and the risk to develop inhibitors among previously untreated patients with severe hemophilia: the CANAL study. Presented at: World Hemophilia Congress; May 21-25, 2006; Vancouver, BC. Abstract 14, PO 386.
21. Manuel DC. Intensive exposure to factor VIII may be a risk factor for inhibitor development in mild hemophilia A. Semin Hematol 2006; 43 (Suppl 1): S89.
22. Morado M, Villar A, Jimenez Y, et al. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11: 79-83.
23. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-427.